The DUSP1 Knockout HCT 116 Polyclonal Cells provide a loss-of-function model generated by CRISPR/Cas9-mediated disruption of the DUSP1 gene in HCT 116 human colorectal carcinoma cells. This polyclonal knockout population enables study of MAP kinase signaling regulation, allowing interrogation of DUSP1 deficiency on stress responses, proliferation, and apoptosis without clonal selection artifacts. These gene-edited cells are suitable for functional assays including Western blotting, quantitative PCR, and phenotypic analyses.
HCT 116 is a widely characterized human colorectal carcinoma epithelial cell line harboring an MLH1 mutation that results in microsatellite instability (MSI) and a KRAS G13D oncogenic mutation. This genetic background drives constitutive activation of the MAPK/ERK pathway and predisposes the cells to altered apoptotic and drug sensitivity profiles. The cell line is a standard model for colorectal cancer research, particularly in studies of chemoresistance, apoptosis, and tumor cell signaling, making it a relevant platform for investigating the regulatory role of DUSP1.
DUSP1 (MKP-1) is a nuclear dual-specificity phosphatase that negatively regulates MAPK signaling by dephosphorylating both threonine and tyrosine residues in the activation loops of ERK1/2, JNK1/2/3, and p38 MAPK. Its expression is rapidly induced by inflammatory and stress stimuli such as TNF, IL-1, LPS, oxidative stress, and heat shock, and by transcription factors AP-1, NF-??B, and p53. As a critical feedback attenuator, DUSP1 directly interacts with these MAPKs to modulate cell proliferation, apoptosis, and stress responses. It functions within a network involving upstream components like EGFR, KRAS, BRAF, MEK1/2, and MAP3Ks (e.g., ASK1, MEKK1), as well as MAP2Ks (MKK4/7, MKK3/6).
In the HCT 116 background, loss of DUSP1 is anticipated to potentiate MAPK signaling due to loss of a key negative checkpoint. Combined with the oncogenic KRAS G13D mutation that sustains MEK/ERK activity, DUSP1 disruption may elevate phospho-ERK, -JNK, and -p38 levels, impacting proliferation, survival, and drug response. This synergy makes the DUSP1 knockout a valuable tool for exploring phosphatase modulation of oncogenic signaling in MSI colorectal cancer.
Researchers can use this model to study MAPK signaling dynamics, stress-induced apoptosis, and chemoresistance. Key applications include Western blotting for DUSP1 and phospho-MAPKs, RT-qPCR, proliferation and apoptosis assays, flow cytometry for phospho-ERK/JNK/p38, drug sensitivity testing with cisplatin or oxaliplatin, and migration/invasion assays. Genomic PCR and sequencing confirm CRISPR edits. For further information, please contact Ascent Research.
